VEGF antibody plus chemo shows activity in prostate Ca

PSA decline of >50% observed in three-fourths of patients, partialresponse seen in 44%

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria